
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (24): 2997-3004.DOI: 10.12114/j.issn.1007-9572.2023.0029
Special Issue: 男性健康最新文章合辑; 运动相关研究最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2022-12-19
Revised:2023-03-16
Published:2023-08-20
Online:2023-04-03
Contact:
SUN Lixia
通讯作者:
孙丽霞
作者简介:基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0029
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
|---|---|---|---|---|---|---|---|
| 一般情况 | |||||||
| 年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
| 高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
| 高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
| 降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
| 饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
| 吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
| 体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
| 人体测量学指标 | |||||||
| 体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
| BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
| 腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
| SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
| DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
| 生化检测指标 | |||||||
| 空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
| hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
| 三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
| 总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
| HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
| LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
Table 1 Comparison of epidemiological survey data of the subjects
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | 检验统计量值 | P值 |
|---|---|---|---|---|---|---|---|
| 一般情况 | |||||||
| 年龄( | 36.9±7.7 | 34.9±7.8 | 35.4±7.4 | 37.2±7.2a | 40.1±7.3abc | 23.26d | <0.01 |
| 高脂血症〔例(%)〕 | 361(39.07) | 49(22.27) | 85(35.42) | 105(45.65) | 122(52.14)abc | 48.39 | <0.01 |
| 高血压〔例(%)〕 | 318(34.42) | 59(26.82) | 62(25.83) | 80(34.78) | 117(50.00)abc | 38.65 | <0.01 |
| 降压药史〔例(%)〕 | 92(9.96) | 11(5.00) | 16(6.67) | 23(10.00) | 42(17.95)abc | 25.60 | <0.01 |
| 饮酒史〔例(%)〕 | 519(56.17) | 117(53.18) | 126(52.50) | 135(58.70) | 141(60.26) | 4.29 | 0.23 |
| 吸烟史〔例(%)〕 | 566(61.26) | 143(65.00) | 146(60.83) | 143(62.17) | 134(57.26) | 2.97 | 0.40 |
| 体育锻炼〔例(%)〕 | 344(37.23) | 84(38.18) | 87(36.25) | 97(42.17) | 76(32.48) | 4.85 | 0.18 |
| 人体测量学指标 | |||||||
| 体质量( | 76.26±12.32 | 75.51±11.94 | 76.05±12.47 | 76.10±13.08 | 77.33±11.76 | 0.90d | 0.44 |
| BMI( | 26.29±3.85 | 25.93±3.80 | 26.08±3.83 | 26.31±4.21 | 26.83±3.50 | 2.42d | 0.06 |
| 腰围( | 89.66±9.68 | 89.18±9.46 | 88.91±9.68 | 89.36±10.43 | 91.16±9.02 | 2.61d | 0.05 |
| SBP( | 134±14 | 133±12 | 132±15 | 135±14 | 137±14ab | 6.42d | <0.01 |
| DBP( | 85±12 | 84±12 | 84±12 | 85±13 | 88±10ab | 7.45d | <0.01 |
| 生化检测指标 | |||||||
| 空腹血糖〔M(P25,P75),mmol/L〕 | 5.40(5.00,5.82) | 4.74(4.50,4.88) | 5.20(5.10,5.30)a | 5.57(5.50,5.69)ab | 6.22(5.99,6.59)abc | 374.54e | <0.01 |
| hs-CRP〔M(P25,P75),mg/L〕 | 0.24(0.01,1.40) | 1.19(0.30,2.60) | 0.25(0.01,1.70)a | 0.16(0.01,1.10)a | 0.11(0.01,0.36)ab | 115.97e | <0.01 |
| 三酰甘油〔M(P25,P75),mmol/L〕 | 1.23(0.83,1.95) | 1.00(0.75,1.59) | 1.19(0.80,1.84) | 1.32(0.84,2.12)a | 1.34(1.00,2.13)a | 23.33e | <0.01 |
| 总胆固醇( | 4.79±1.10 | 4.55±0.96 | 4.64±1.00 | 4.99±1.32ab | 4.96±1.03ab | 9.52d | <0.01 |
| HDL-C( | 1.40±0.35 | 1.45±0.40 | 1.42±0.37 | 1.38±0.33 | 1.35±0.30a | 4.58d | <0.01 |
| LDL-C( | 2.81±0.82 | 2.68±0.76 | 2.76±0.71 | 2.81±0.71 | 2.98±1.05ab | 5.22d | <0.01 |
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
|---|---|---|---|---|---|---|---|
| SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
| SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
| ∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
| DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
| DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
| ∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
| MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
| MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
| ∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
| HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
| HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
| ∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
| baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
| baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
| ∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
| MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
| VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
| 峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
| Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
Table 2 Comparison of baPWV-related data before and after the secondary load test of the power vehicle bicycle
| 变量 | 总人群(N=924) | Q1组(n=220) | Q2组(n=240) | Q3组(n=230) | Q4组(n=234) | F(H)值 | P值 |
|---|---|---|---|---|---|---|---|
| SBP1( | 132±15 | 130±14 | 131±15 | 132±16 | 135±16ab | 4.15 | <0.01 |
| SBP2( | 132±15 | 130±14 | 132±15 | 132±15 | 135±15ab | 6.01 | <0.01 |
| ∆SBP〔M(P25,P75),mmHg〕 | 1(-5,6) | 0(-7,6) | 1(-4,6) | 0(-5,6) | 1(-5,7) | 4.54e | 0.21 |
| DBP1( | 79±11 | 77±11 | 78±11 | 79±11 | 82±10ab | 8.04 | <0.01 |
| DBP2( | 79±11 | 78±11 | 78±11 | 79±11 | 82±10abc | 9.62 | <0.01 |
| ∆DBP〔M(P25,P75),mmHg〕 | 0(-3,4) | 0(-3,4) | 0(-4,5) | 0(-3,4) | 1(-3,5) | 1.86e | 0.60 |
| MAP1( | 99.17±12.50 | 97.23±12.19 | 98.03±12.24 | 99.28±13.03 | 102.04±12.08ab | 6.66 | <0.01 |
| MAP2( | 99.44±11.98 | 97.57±11.14 | 98.74±12.14 | 99.39±12.10 | 101.97±12.10ab | 5.63 | <0.01 |
| ∆MAP〔M(P25,P75),mmHg〕 | 0.30(-4.20,5.10) | 0.80(-3.70,5.40) | 0.30(-3.80,5.50) | -0.05(-4.70,4.30) | -0.15(-4.50,4.90) | 1.70e | 0.64 |
| HR1( | 80±13 | 80±12 | 79±12 | 81±12 | 81±12 | 2.14 | 0.09 |
| HR2( | 86±14d | 85±13d | 85±14d | 85±12d | 87±14 | 1.34 | 0.26 |
| ∆HR〔M(P25,P75),次/min〕 | 5(0,10) | 6(0,11) | 5(0,11) | 4(-1,8) | 5(0,11) | 5.29e | 0.15 |
| baPWV1( | 1 375.98±209.61 | 1 351.63±198.92 | 1 345.50±204.86 | 1 384.63±216.83 | 1 421.65±209.58abc | 6.63 | <0.01 |
| baPWV2( | 1 342.24±208.82d | 1 309.95±194.19d | 1 312.10±208.65d | 1 343.84±203.35d | 1 401.92±215.65abcd | 10.08 | <0.01 |
| ∆baPWV〔M(P25,P75),cm/s〕 | -36.0 (-87.0,24.0) | -45.5 (-93.0,12.5) | -36.5 (-85.0,19.5) | -39.5 (-95.0,18.0) | -23.0 (-77.0,35.0) | 7.51e | 0.06 |
| MET( | 12.16±2.55 | 12.42±2.78 | 12.21±2.26 | 12.22±2.78 | 11.79±2.33 | 2.49 | 0.06 |
| VO2max( | 42.56±8.91 | 43.50±9.71 | 42.73±7.89 | 42.78±9.74 | 41.29±8.14 | 2.49 | 0.06 |
| 峰值HR( | 139.35±14.65 | 139.40±14.90 | 139.25±15.62 | 140.14±13.69 | 138.61±14.33 | 0.43 | 0.73 |
| Time( | 7.13(4.94,11.16) | 7.51(5.41,11.37) | 7.38(4.92,12.61) | 7.03(5.00,11.15) | 6.67(4.73,9.55) | 8.22e | 0.06 |
| 模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
|---|---|---|---|---|---|
| 模型1 | Q4 | ||||
| Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
| Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
| Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
| 模型2 | Q4 | ||||
| Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
| Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
| Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
| 模型3 | Q4 | ||||
| Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
| Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
| Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
Table 3 Generalized linear model analysis of the effect of fasting blood glucose level on baPWV before and after the secondary load test of the power vehicle bicycle
| 模型 | 自变量 | B(95%CI) | SE | t值 | P值 |
|---|---|---|---|---|---|
| 模型1 | Q4 | ||||
| Q1 | -30.10(-47.39,-12.82) | 8.81 | 6.66 | <0.01 | |
| Q2 | -22.54(-39.48,-5.60) | 8.63 | -2.61 | 0.01 | |
| Q3 | -25.38(-42.39,-8.37) | 8.67 | -2.93 | <0.01 | |
| 模型2 | Q4 | ||||
| Q1 | -18.82(-36.69,-0.94) | 9.11 | -2.07 | 0.04 | |
| Q2 | -12.71(-29.74,4.32) | 8.68 | -1.47 | 0.14 | |
| Q3 | -19.58(-36.45,-2.71) | 8.60 | -2.28 | 0.02 | |
| 模型3 | Q4 | ||||
| Q1 | -18.96(-36.96,-0.96) | 9.17 | -2.07 | 0.04 | |
| Q2 | -12.37(-29.35,4.60) | 8.65 | -1.43 | 0.15 | |
| Q3 | -15.23(-31.95,1.49) | 8.52 | -1.79 | 0.07 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
韩旭,刘倩,马一涵,等. 非糖尿病人群空腹血糖水平对动脉僵硬度进展的影响[J]. 中华高血压杂志,2021,29(1):41-47. DOI:10.16439/j.issn.1673-7245.2021.01.010.
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
体育总局关于开展第五次国民体质监测的通知[EB/OL].(2019-02-02)[2022-08-02].
|
| [23] |
|
| [24] |
|
| [25] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56.
|
| [26] |
中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35(5):390-419. DOI:10.3760/j.issn:0253-3758.2007.05.003.
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [1] | TANG Haoqing, LI Mingyue, LONG Ren, ZHU Yinbo, LIANG Weihuan, ZHU Ping, ZHAO Wei, ZHAO Yang, LIU Xiaoyun. Management Burden of Diabetic Mellitus Patients with Multimorbidity among Middle Aged and Older Adults: a Cross-sectional Survey in 6 Community Medical Institutes of China [J]. Chinese General Practice, 2026, 29(32): 4786-4797. |
| [2] | YI Shanye, YANG Rong, LIAO Xiaoyang, ZHOU Yiheng, LIU Lidi, YANG Ziyu, BAI Jiaxin, JIA Yu, ZHANG Xin. Interpretation of the 2024 Blood Pressure Measurement and Assessment of Arterial Structure and Function: an Expert Group Position Paper [J]. Chinese General Practice, 2026, 29(32): 4690-4694. |
| [3] | China Sport Science Society. Guidelines for Exercise Prescription of Dyslipidemia [J]. Chinese General Practice, 2026, 29(32): 4673-4689. |
| [4] | TIAN Xiangyang, ZHOU Yingsheng, GAO Ying. Prospects of Behavioral and Lifestyle Interventions for Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(31): 4513-4520. |
| [5] | XIAO Zhili, LU Chenxia, ZHU Hui, ZHANG Jia, CHEN Zhuangzhuang, SUN Wei, LIU Xiangchuxuan, LUO Cheng, XIAO Mingzhong, LI Xiaodong. Application and Future Prospects of CGM Technology in Co-management of MAFLD and T2DM [J]. Chinese General Practice, 2026, 29(31): 4521-4527. |
| [6] | YAN Ziwei, NIE Jiahua, SHI Yan, WEI Limin. Correlation between the Albumin/Gamma-glutamyl Transferase Ratio and Metabolic-associated Fatty Liver Disease in Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(30): 4431-4437. |
| [7] | LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479. |
| [8] | HE Qizhen, ZHONG Qingling, XU Jin, YU Yi, ZHAO Yuefei. Perceptions and Experiences of Zero-time Exercise among Community-dwelling Older Adults: a Qualitative Study [J]. Chinese General Practice, 2026, 29(30): 4480-4488. |
| [9] | TANG Bo, YANG Rui, ZHAO Qian, LIU Hong, LIU Lidi, ZHANG Ying, JIANG Lihua, WANG Xiaogang, YANG Rong, LIAO Xiaoyang. Interpretation of the 2024 U.S. Preventive Services Task Force Recommendation Statement on Fall Prevention in Community-dwelling Older Adults [J]. Chinese General Practice, 2026, 29(30): 4360-4365. |
| [10] | ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336. |
| [11] | WANG Lin, CAO Chenchen, HUANG Yichong, LIU Jing. Development of Preference Attributes and Levels of Family Doctor Contract Services for Patients with Comorbidity of Hypertension and Type 2 Diabetes Mellitus Based on Discrete Choice Experiments [J]. Chinese General Practice, 2026, 29(29): 4232-4240. |
| [12] | LU Hongrun, ZHANG Rui, ZHAO Yu, LI Jiazhen, WANG Weiqiang. Association of Cardiometabolic Comorbidity with Estimated Glomerular Filtration Rate [J]. Chinese General Practice, 2026, 29(28): 4179-4186. |
| [13] | JIANG Chen, AN Ni, XU Yunjing, NIU Shaona, LI Fengming, JIANG Liangmei. A Cross-sectional Study of Hospitalization Characteristics and Healthcare Resource Consumption of Patients with Cardiovascular-kidney-metabolic Syndrome [J]. Chinese General Practice, 2026, 29(28): 4172-4178. |
| [14] | YU Xinyan, ZHANG Fang, GU Zhile, WANG Yanfang, SU Peng, ZHANG Haicheng. Correlation between Fasting Plasma Glucose, Body Mass Index, and Waist Circumference among Community-dwelling Elderly Individuals [J]. Chinese General Practice, 2026, 29(28): 4132-4140. |
| [15] | WU Yuqiong, CHU Xiangling, HUANG Youye, SUN Li, JIANG Tian, ZHANG Qiu, HU Honglin. A Case Report and Literature Review of Hepatocyte Nuclear Factor 4α Gene Mutation Leading to Maturity-onset Diabetes of the Young [J]. Chinese General Practice, 2026, 29(27): 4011-4015. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||